- Home
- UHG vs EPRX Comparison
UHG vs EPRX Comparison
Compare UHG & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- EPRX
- Stock Information
- Founded
- UHG 2004
- EPRX 2011
- Country
- UHG United States
- EPRX Canada
- Employees
- UHG N/A
- EPRX N/A
- Industry
- UHG Homebuilding
- EPRX
- Sector
- UHG Consumer Discretionary
- EPRX
- Exchange
- UHG Nasdaq
- EPRX NYSE
- Market Cap
- UHG 158.8M
- EPRX 137.7M
- IPO Year
- UHG N/A
- EPRX N/A
- Fundamental
- Price
- UHG $3.14
- EPRX $5.47
- Analyst Decision
- UHG
- EPRX Strong Buy
- Analyst Count
- UHG 0
- EPRX 1
- Target Price
- UHG N/A
- EPRX $12.00
- AVG Volume (30 Days)
- UHG 231.7K
- EPRX 11.6K
- Earning Date
- UHG 08-07-2025
- EPRX 08-07-2025
- Dividend Yield
- UHG N/A
- EPRX N/A
- EPS Growth
- UHG N/A
- EPRX N/A
- EPS
- UHG 0.76
- EPRX N/A
- Revenue
- UHG $449,877,017.00
- EPRX N/A
- Revenue This Year
- UHG N/A
- EPRX N/A
- Revenue Next Year
- UHG N/A
- EPRX N/A
- P/E Ratio
- UHG $4.06
- EPRX N/A
- Revenue Growth
- UHG 5.24
- EPRX N/A
- 52 Week Low
- UHG $1.60
- EPRX $2.20
- 52 Week High
- UHG $6.93
- EPRX $6.20
- Technical
- Relative Strength Index (RSI)
- UHG 49.50
- EPRX N/A
- Support Level
- UHG $2.71
- EPRX N/A
- Resistance Level
- UHG $2.95
- EPRX N/A
- Average True Range (ATR)
- UHG 0.33
- EPRX 0.00
- MACD
- UHG -0.07
- EPRX 0.00
- Stochastic Oscillator
- UHG 28.24
- EPRX 0.00
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.